Technical Analysis for NKTX - Nkarta, Inc.

Grade Last Price % Change Price Change
F 25.92 -5.30% -1.45
NKTX closed down 5.3 percent on Thursday, May 6, 2021, on 1.22 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical NKTX trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -5.30%
Older End-of-Day Signals for NKTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% about 15 hours ago
Down 1 ATR about 15 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
Down 5% about 20 hours ago
Down 3% about 21 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Lymphoma Cancer Treatments Gene Therapy Virotherapy Tumor Cancer Treatment Therapies For Cancer Chimeric Antigen Receptor CD19 Chimeric Antigen Receptor T Cell Tumor Cell Natural Killer Cell Antigen

Is NKTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 79.16
52 Week Low 22.4602
Average Volume 238,352
200-Day Moving Average 38.96
50-Day Moving Average 37.64
20-Day Moving Average 32.60
10-Day Moving Average 30.91
Average True Range 2.61
ADX 24.91
+DI 11.77
-DI 32.63
Chandelier Exit (Long, 3 ATRs ) 30.09
Chandelier Exit (Short, 3 ATRs ) 32.36
Upper Bollinger Band 38.07
Lower Bollinger Band 27.12
Percent B (%b) -0.11
BandWidth 33.58
MACD Line -2.52
MACD Signal Line -2.14
MACD Histogram -0.3786
Fundamentals Value
Market Cap 844.87 Million
Num Shares 32.6 Million
EPS -0.88
Price-to-Earnings (P/E) Ratio -29.54
Price-to-Sales 1000000.00
Price-to-Book 3.48
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.99
Resistance 3 (R3) 29.97 28.60 29.31
Resistance 2 (R2) 28.60 27.56 28.61 29.08
Resistance 1 (R1) 27.26 26.93 26.58 27.28 28.86
Pivot Point 25.89 25.89 25.55 25.90 25.89
Support 1 (S1) 24.55 24.85 23.87 24.57 22.98
Support 2 (S2) 23.18 24.22 23.19 22.76
Support 3 (S3) 21.84 23.18 22.53
Support 4 (S4) 21.86